EP1861509A4 - METHOD OF PREDICTING SURVIVAL WITHOUT PROGRESSION AND GLOBAL SURVIVAL, EVERYWHERE OF FOLLOW-UP, DURING THE TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER USING CIRCULATING TUMOR CELLS - Google Patents

METHOD OF PREDICTING SURVIVAL WITHOUT PROGRESSION AND GLOBAL SURVIVAL, EVERYWHERE OF FOLLOW-UP, DURING THE TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER USING CIRCULATING TUMOR CELLS

Info

Publication number: EP1861509A4
Authority: EP; European Patent Office
Prior art keywords: survival; everywhere; progression; patients; follow
Prior art date: 2005-03-14
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

EP20050725638

Other languages

German (de)

French (fr)

Other versions

EP1861509A2 (en

EP1861509B1 (en

Inventor

Jeffrey W Allard

Gerald V Doyle

Daniel F Hayes

Michael Craig Miller

Leon W M M Terstappen

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Janssen Diagnostics LLC

Original Assignee

Immunivest Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-03-14

Filing date

2005-03-14

Publication date

2010-04-14

2005-03-14 Application filed by Immunivest Corp filed Critical Immunivest Corp

2005-03-14 Priority to PL05725638T priority Critical patent/PL1861509T3/en

2007-12-05 Publication of EP1861509A2 publication Critical patent/EP1861509A2/en

2010-04-14 Publication of EP1861509A4 publication Critical patent/EP1861509A4/en

2015-09-09 Application granted granted Critical

2015-09-09 Publication of EP1861509B1 publication Critical patent/EP1861509B1/en

2025-03-14 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Chemical & Material Sciences (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Biotechnology (AREA)
Microbiology (AREA)
Cell Biology (AREA)
Food Science & Technology (AREA)
Medicinal Chemistry (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Investigating Or Analysing Biological Materials (AREA)

EP05725638.0A 2005-03-14 2005-03-14 A method for predicting progression free and overall survival at each follow-up time point during therapy of metastatic breast cancer patients using circulating tumor cells Expired - Lifetime EP1861509B1 (en)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
PL05725638T PL1861509T3 (en)	2005-03-14	2005-03-14	A method for predicting progression free and overall survival at each follow-up time point during therapy of metastatic breast cancer patients using circulating tumor cells

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
PCT/US2005/008602 WO2006104474A2 (en)	2005-03-14	2005-03-14	A method for predicting progression free and overall survival at each follow-up time point during therapy of metastatic breast cancer patients using circulating tumor cells

Publications (3)

Publication Number	Publication Date
EP1861509A2 EP1861509A2 (en)	2007-12-05
EP1861509A4 true EP1861509A4 (en)	2010-04-14
EP1861509B1 EP1861509B1 (en)	2015-09-09

Family

ID=37053815

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP05725638.0A Expired - Lifetime EP1861509B1 (en)	2005-03-14	2005-03-14	A method for predicting progression free and overall survival at each follow-up time point during therapy of metastatic breast cancer patients using circulating tumor cells

Country Status (6)

Country	Link
EP (1)	EP1861509B1 (en)
JP (1)	JP2008533487A (en)
CA (1)	CA2600225C (en)
DK (1)	DK1861509T3 (en)
PL (1)	PL1861509T3 (en)
WO (1)	WO2006104474A2 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ITBO20040420A1 (en)	2004-07-07	2004-10-07	Type S R L	METAL CUTTING AND FORMING MACHINE
ITBO20050481A1 (en)	2005-07-19	2007-01-20	Silicon Biosystems S R L	METHOD AND APPARATUS FOR THE HANDLING AND / OR IDENTIFICATION OF PARTICLES
US7993821B2 (en)	2005-08-11	2011-08-09	University Of Washington	Methods and apparatus for the isolation and enrichment of circulating tumor cells
US8173413B2 (en)	2005-08-11	2012-05-08	University Of Washington	Separation and concentration of biological cells and biological particles using a one-dimensional channel
ITBO20050646A1 (en)	2005-10-26	2007-04-27	Silicon Biosystem S R L	METHOD AND APPARATUS FOR CHARACTERIZATION AND COUNTING OF PARTICLES
ITTO20060226A1 (en)	2006-03-27	2007-09-28	Silicon Biosystem S P A	METHOD AND APPARATUS FOR PROCESSING AND OR ANALYSIS AND OR SELECTION OF PARTICLES, IN PARTICULAR BIOLOGICAL PARTICLES
MX2008015425A (en)	2006-06-02	2008-12-12	Pfizer Prod Inc	Circulating tumor cell assay.
US20080050739A1 (en)	2006-06-14	2008-02-28	Roland Stoughton	Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats
EP2589668A1 (en)	2006-06-14	2013-05-08	Verinata Health, Inc	Rare cell analysis using sample splitting and DNA tags
US8841135B2 (en)	2007-06-20	2014-09-23	University Of Washington	Biochip for high-throughput screening of circulating tumor cells
ITTO20070771A1 (en)	2007-10-29	2009-04-30	Silicon Biosystems Spa	METHOD AND APPARATUS FOR IDENTIFICATION AND HANDLING OF PARTICLES
US8071395B2 (en)	2007-12-12	2011-12-06	The Board Of Trustees Of The Leland Stanford Junior University	Methods and apparatus for magnetic separation of cells
US10895575B2 (en)	2008-11-04	2021-01-19	Menarini Silicon Biosystems S.P.A.	Method for identification, selection and analysis of tumour cells
IT1391619B1 (en)	2008-11-04	2012-01-11	Silicon Biosystems Spa	METHOD FOR THE IDENTIFICATION, SELECTION AND ANALYSIS OF TUMOR CELLS
CA2782123C (en)	2009-03-17	2017-05-02	Silicon Biosystems S.P.A.	Microfluidic device for isolation of cells
JP6017845B2 (en) *	2011-06-10	2016-11-02	帝人ファーマ株式会社	Method for detecting cells lacking GPI anchor protein
ITTO20110990A1 (en)	2011-10-28	2013-04-29	Silicon Biosystems Spa	METHOD AND APPARATUS FOR OPTICAL ANALYSIS OF LOW TEMPERATURE PARTICLES
ITBO20110766A1 (en)	2011-12-28	2013-06-29	Silicon Biosystems Spa	DEVICES, EQUIPMENT, KITS AND METHOD FOR THE TREATMENT OF A BIOLOGICAL SAMPLE
RU2547561C1 (en) *	2013-12-18	2015-04-10	Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Ульяновский государственный университет"	Method for predicting five-year survival rate in patients with infiltrating breast cancer by determining total score of malignancy
US11371982B2 (en)	2016-01-19	2022-06-28	Tosoh Corporation	Method of predicting patient prognosis using rare cells
JP7326764B2 (en)	2018-03-09	2023-08-16	東ソー株式会社	Tumor markers and methods for recovering and detecting tumor cells distinct from contaminant cells
JP2019158777A (en) *	2018-03-16	2019-09-19	東ソー株式会社	Tumor marker and method for collecting and detecting tumor cell by distinguishing it from contaminant cell
JP7521750B2 (en) *	2020-01-14	2024-07-24	学校法人杏林学園	Methods for detecting epithelial marker-negative tumor cells
BR112022015011A2 (en)	2020-01-29	2022-09-20	Corcept Therapeutics Inc	METHOD TO TREAT A SUBJECT SUFFERING FROM ADRENOCORTICAL CARCINOMA TUMOR AND HAVING EXCESS OF CORTISOL, AND, PHARMACEUTICAL COMPOSITION TO TREAT ADRENOCORTICAL CARCINOMA
JP7593584B2 (en) *	2020-03-10	2024-12-03	学校法人杏林学園	Tumor cell markers and methods for detecting or harvesting tumor cells - Patents.com
AU2021336112A1 (en) *	2020-09-02	2023-05-04	Menarini Silicon Biosystems S.P.A.	System, kit, method and process for handling a sample
CN113284612B (en) *	2021-05-21	2024-04-16	大连海事大学	A survival analysis method based on XGBoost algorithm
WO2023180465A1 (en) *	2022-03-23	2023-09-28	University Of Twente	A magnetic micro-needle to isolate single immunomagnetically labeled cells

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5993388A (en) *	1997-07-01	1999-11-30	Kattan; Michael W.	Nomograms to aid in the treatment of prostatic cancer
WO1999041613A1 (en) *	1998-02-12	1999-08-19	Immunivest	Methods and reagents for the rapid and efficient isolation of circulating cancer cells
AU2876900A (en) *	1999-02-10	2000-08-29	Cell Works Inc.	Class characterization of circulating cancer cells isolated from body fluids andmethods of use
EP1425294B2 (en) *	2001-08-23	2012-12-12	Veridex, LLC	Analysis of circulating tumor cells, fragments, and debris
AU2003242815A1 (en) *	2002-03-13	2003-09-22	Biomerieux	Method for the characterisation of circulating tumour cells stemming from solid cancers
EP1597353B1 (en) *	2003-02-27	2010-11-24	Veridex, LLC	CIRCULATING TUMOR CELLS (CTC's): EARLY ASSESSMENT OF TIME TO PROGRESSION SURVIVAL AND RESPONSE TO THERAPY IN METASTATIC CANCER PATIENTS

2005
- 2005-03-14 CA CA2600225A patent/CA2600225C/en not_active Expired - Lifetime
- 2005-03-14 PL PL05725638T patent/PL1861509T3/en unknown
- 2005-03-14 EP EP05725638.0A patent/EP1861509B1/en not_active Expired - Lifetime
- 2005-03-14 JP JP2008501850A patent/JP2008533487A/en active Pending
- 2005-03-14 WO PCT/US2005/008602 patent/WO2006104474A2/en not_active Ceased
- 2005-03-14 DK DK05725638.0T patent/DK1861509T3/en active

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CRISTOFANILLI MASSIMO ET AL: "Circulating tumor cells, disease progression, and survival in metastatic breast cancer", NEW ENGLAND JOURNAL OF MEDICINE, vol. 351, no. 8, 19 August 2004 (2004-08-19), pages 781 - 791, XP002570580, ISSN: 0028-4793 *
CRISTOFANILLI MASSIMO ET AL: "Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer.", JOURNAL OF CLINICAL ONCOLOGY : OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY 1 MAR 2005, vol. 23, no. 7, 1 March 2005 (2005-03-01), pages 1420 - 1430, XP002570579, ISSN: 0732-183X *
See also references of WO2006104474A2 *

Also Published As

Publication number	Publication date
CA2600225A1 (en)	2006-10-05
WO2006104474A3 (en)	2007-02-22
EP1861509A2 (en)	2007-12-05
CA2600225C (en)	2016-06-28
WO2006104474A2 (en)	2006-10-05
JP2008533487A (en)	2008-08-21
EP1861509B1 (en)	2015-09-09
PL1861509T3 (en)	2016-01-29
DK1861509T3 (en)	2015-12-07

Legal Events

Date	Code	Title	Description
2007-11-02	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2007-12-05	17P	Request for examination filed	Effective date: 20070924
2007-12-05	AK	Designated contracting states	Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR
2008-06-18	DAX	Request for extension of the european patent (deleted)
2010-04-14	A4	Supplementary search report drawn up and despatched	Effective date: 20100317
2011-05-04	17Q	First examination report despatched	Effective date: 20110401
2015-02-18	RAP1	Party data changed (applicant data changed or rights of an application transferred)	Owner name: JANSSEN DIAGNOSTICS, LLC
2015-04-10	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2015-05-06	INTG	Intention to grant announced	Effective date: 20150410
2015-07-29	GRAS	Grant fee paid	Free format text: ORIGINAL CODE: EPIDOSNIGR3
2015-08-07	GRAA	(expected) grant	Free format text: ORIGINAL CODE: 0009210
2015-09-09	AK	Designated contracting states	Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR
2015-09-09	REG	Reference to a national code	Ref country code: GB Ref legal event code: FG4D
2015-09-15	REG	Reference to a national code	Ref country code: AT Ref legal event code: REF Ref document number: 748169 Country of ref document: AT Kind code of ref document: T Effective date: 20150915 Ref country code: CH Ref legal event code: EP
2015-09-30	REG	Reference to a national code	Ref country code: CH Ref legal event code: NV Representative=s name: WEINMANN ZIMMERLI, CH
2015-10-07	REG	Reference to a national code	Ref country code: IE Ref legal event code: FG4D
2015-10-22	REG	Reference to a national code	Ref country code: DE Ref legal event code: R096 Ref document number: 602005047456 Country of ref document: DE
2015-12-02	REG	Reference to a national code	Ref country code: NL Ref legal event code: FP
2015-12-07	REG	Reference to a national code	Ref country code: DK Ref legal event code: T3 Effective date: 20151201
2015-12-22	REG	Reference to a national code	Ref country code: SE Ref legal event code: TRGR
2016-01-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151210 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150909 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150909
2016-02-08	REG	Reference to a national code	Ref country code: FR Ref legal event code: PLFP Year of fee payment: 12
2016-02-10	REG	Reference to a national code	Ref country code: LT Ref legal event code: MG4D
2016-02-15	REG	Reference to a national code	Ref country code: AT Ref legal event code: UEP Ref document number: 748169 Country of ref document: AT Kind code of ref document: T Effective date: 20150909
2016-02-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150909
2016-04-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150909 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150909 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160109 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150909
2016-05-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160111 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150909
2016-06-10	REG	Reference to a national code	Ref country code: DE Ref legal event code: R097 Ref document number: 602005047456 Country of ref document: DE
2016-07-15	PLBE	No opposition filed within time limit	Free format text: ORIGINAL CODE: 0009261
2016-07-15	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT
2016-08-17	26N	No opposition filed	Effective date: 20160610
2016-08-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150909
2016-10-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150909
2017-02-13	REG	Reference to a national code	Ref country code: FR Ref legal event code: PLFP Year of fee payment: 13
2018-05-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150909 Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20050314
2018-07-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150909
2018-08-24	REG	Reference to a national code	Ref country code: FR Ref legal event code: PLFP Year of fee payment: 14
2023-07-12	P01	Opt-out of the competence of the unified patent court (upc) registered	Effective date: 20230530
2024-03-22	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: LU Payment date: 20240227 Year of fee payment: 20
2024-04-16	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: IE Payment date: 20240223 Year of fee payment: 20 Ref country code: NL Payment date: 20240226 Year of fee payment: 20
2024-04-23	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: AT Payment date: 20240226 Year of fee payment: 20
2024-04-30	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: DE Payment date: 20240220 Year of fee payment: 20 Ref country code: GB Payment date: 20240222 Year of fee payment: 20
2024-05-31	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: TR Payment date: 20240219 Year of fee payment: 20 Ref country code: SE Payment date: 20240226 Year of fee payment: 20 Ref country code: PL Payment date: 20240216 Year of fee payment: 20 Ref country code: IT Payment date: 20240227 Year of fee payment: 20 Ref country code: FR Payment date: 20240223 Year of fee payment: 20 Ref country code: DK Payment date: 20240314 Year of fee payment: 20 Ref country code: BE Payment date: 20240229 Year of fee payment: 20
2024-07-18	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: CH Payment date: 20240401 Year of fee payment: 20
2025-03-14	REG	Reference to a national code	Ref country code: DE Ref legal event code: R071 Ref document number: 602005047456 Country of ref document: DE Ref country code: CH Ref legal event code: PL
2025-03-17	REG	Reference to a national code	Ref country code: DK Ref legal event code: EUP Expiry date: 20250314
2025-03-19	REG	Reference to a national code	Ref country code: NL Ref legal event code: MK Effective date: 20250313
2025-04-02	REG	Reference to a national code	Ref country code: GB Ref legal event code: PE20 Expiry date: 20250313
2025-04-22	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: IE Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20250314
2025-04-23	REG	Reference to a national code	Ref country code: IE Ref legal event code: MK9A
2025-04-28	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: GB Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20250313
2025-04-29	REG	Reference to a national code	Ref country code: SE Ref legal event code: EUG
2025-05-15	REG	Reference to a national code	Ref country code: AT Ref legal event code: MK07 Ref document number: 748169 Country of ref document: AT Kind code of ref document: T Effective date: 20250314
2025-06-05	REG	Reference to a national code	Ref country code: BE Ref legal event code: MK Effective date: 20250314

Publication	Publication Date	Title
EP1861509A4 (en)	2010-04-14	METHOD OF PREDICTING SURVIVAL WITHOUT PROGRESSION AND GLOBAL SURVIVAL, EVERYWHERE OF FOLLOW-UP, DURING THE TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER USING CIRCULATING TUMOR CELLS
DE602005007623D1 (en)	2008-07-31	DISORDERSIZED PYRAZOLOBENZODIAZEPINES SUITABLE AS CDK2 AND ANGIOGENESIS INHIBITORS AND FOR THE TREATMENT OF BREAST, COLON, LUNG AND PROSTATE CANCER
PL2100618T3 (en)	2014-07-31	Anti-PDGFR alpha antibody for use in the treatment of metastatic bone cancer
EA200801853A1 (en)	2009-02-27	EFFECTIVE PEPTIDES IN THE TREATMENT OF TUMORS AND OTHER DISEASES THAT REQUIRE REMOVAL OR DESTRUCTION OF CELLS
WO2010059969A8 (en)	2011-02-03	Use of anti-vegf antibody in combination with chemotherapy for treating breast cancer
NO2017019I2 (en)	2017-05-04	Enzalutamide or a pharmaceutically acceptable salt thereof
DK1706112T3 (en)	2014-04-22	METHODS OF TREATING AN INFLAMMATOR-RELATED DISEASE
TNSN05300A1 (en)	2007-07-10	Treatment with anti-vegf antibodies
PL2894162T3 (en)	2018-06-29	Identification of cancer-related antigens for diagnosis and treatment
BRPI0719202A2 (en)	2015-06-16	Diagnosis and treatment of cancer using antiereg antibody
CL2008001234A1 (en)	2008-09-22	COMPOUNDS DERIVED FROM NITROGEN HETEROCICLES, INHIBITORS OF APOPTOSIS PROTEINS; AND USE IN THE TREATMENT OF CANCER.
BRPI0813364A2 (en)	2014-12-30	DIAGNOSTIC METHODS AND CANCER TREATMENT.
NL1025873A1 (en)	2004-10-05	Dosage forms and methods of treatment with vegfr inhibitors.
EP1788050A4 (en)	2009-07-01	AQUEOUS PRIMARY COMPOSITION, SURFACE TREATMENT METHOD USING THE SAME, AND MULTILAYER STRUCTURE
EP3818171A4 (en)	2022-03-30	METHODS FOR DETECTING POPULATIONS OF CELLS ASSOCIATED WITH CANCER, SCREENING FOR METASTATIC CANCER AND RELATED TREATMENTS
WO2006133325A3 (en)	2007-03-15	Analysis of tissue samples surrounding malignancies
EP1756166A4 (en)	2008-08-27	DIAGNOSIS AND TREATMENT OF PROSTATE CANCER
GB0512299D0 (en)	2005-07-27	Diagnosis prognosis and prediction of recurrence of breast cancer
EP1987165A4 (en)	2010-01-27	GENES ACTING ON THE PERFORMANCES OF HUMAN MEMORY
PH12012500296A1 (en)	2012-10-22	Anti-angiogenesis therapy for the treatment of previously treated breast cancer
IS8497A (en)	2006-06-02	Methods and reagents for the treatment of inflammatory diseases
EP1805519A4 (en)	2009-12-02	WNT PROTEINS AND DETECTION AND TREATMENT OF CANCER
CY1117701T1 (en)	2017-05-17	TEMSIRIOLIMUM ACTIVITY AGAINST TUMOR CANCER CELL RADICAL CELLS
WO2007038264A3 (en)	2007-10-11	Gapr-1 methods
EP1474531A4 (en)	2006-06-14	ELECTROPHORETIC ANALYSIS FOR PREDICTING THE RISK OF CANCER AND THE EFFICIENCY AND TOXICITY OF CANCER THERAPY